

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934**

Dated February 2, 2016

Commission File Number 001-36421

---

**AURINIA PHARMACEUTICALS INC.**

(Exact name of Registrant as specified in its charter)

---

N/A

(Translation of Registrant's Name)

#1203-4464 Markham Street  
Victoria, British Columbia  
V8Z7X8

(250) 708-4272

(Address and telephone number of registrant's principle executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: February 2, 2016.

**Aurinia Pharmaceuticals Inc.**

By: /s/ Michael R. Martin

\_\_\_\_\_  
Name: Michael R. Martin

Title: Chief Operating Officer

EXHIBIT INDEX

<u>Exhibit</u>	<u>Description of Exhibit</u>
99.1	News Release – Aurinia Pharmaceuticals to Present at the 18 <sup>th</sup> Annual BIO CEO & Investor Conference

## **Aurinia Pharmaceuticals to Present at the 18<sup>th</sup> Annual BIO CEO & Investor Conference**

VICTORIA, British Columbia--(BUSINESS WIRE)--February 2, 2016--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH) (TSX:AUP) today announced that its Chief Operating Officer, Michael R. Martin will present a corporate overview of the company at the 18<sup>th</sup> annual BIO CEO & Investor Conference, taking place February 8 & 9, 2016 in New York at the Waldorf Astoria Hotel. The presentation will also be available using the webcast link below.

### **Aurinia Presentation Details**

Date: Tuesday, February 9, 2016

Time: 2:00 p.m. Eastern Standard Time

Location: Waldorf Astoria Hotel in the Louis XVI Room

Webcast: <http://www.veracast.com/webcasts/bio/ceoinvestor2016/61225590319.cfm>

### **About Aurinia**

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently collecting data in its 265 patient Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (LN). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.

Voclosporin is a novel and potentially best-in-class calcineurin inhibitor ("CNI") with extensive clinical data in over 2,000 patients in other indications. Voclosporin is made by a modification of a single amino acid of the cyclosporine molecule (a CNI approved for use in transplant patients since 1983). This modification results in a more predictable pharmacokinetic and pharmacodynamic relationship, an increase in potency vs. cyclosporine, an altered metabolic profile, and potential for flat dosing.

Visit [www.auriniapharma.com](http://www.auriniapharma.com) for more information.

### **CONTACT:**

#### **Aurinia Pharmaceuticals**

Stephen Zaruby, (250) 708-4293

President & Chief Executive Officer

or

[szaruby@auriniapharma.com](mailto:szaruby@auriniapharma.com)

Michael R. Martin, (250) 708-4272

Chief Operating Officer

[mmartin@auriniapharma.com](mailto:mmartin@auriniapharma.com)

or

#### **Renmark Financial Communications Inc.**

Barry Mire, (416) 644-2020

[bmire@renmarkfinancial.com](mailto:bmire@renmarkfinancial.com)

or

Laura Welsh, (514) 939-3989

[lwelsh@renmarkfinancial.com](mailto:lwelsh@renmarkfinancial.com)